MBX Biosciences, Inc. filed a Current Report on Form 8-K on August 6, 2026, announcing its financial results for the quarter ended June 30, 2026, providing a clinical trial update for its lead candidate MBX 4291, and furnishing an updated corporate presentation under Regulation FD.

Key Highlights

  • Quarterly results announced: MBX Biosciences disclosed financial results for the quarter ended June 30, 2026, furnished as Exhibit 99.1.
  • Clinical trial on track: The company reported it remains on track to report data from the first cohort of the 12-week multiple ascending dose (Part C) of the MBX 4291 Phase 1 trial in the fourth quarter of 2026.
  • Dosing regimen disclosed: The first cohort in Part C is evaluating a 30 mg (once-weekly times four) plus 120 mg (once-monthly) plus 180 mg (once-monthly) titration regimen in adult participants with obesity (body mass index of 30 or greater).
  • Corporate presentation updated: An updated corporate presentation was furnished as Exhibit 99.2 under Item 7.01 Regulation FD Disclosure.
  • Emerging growth company: According to the filing, MBX Biosciences is designated as an emerging growth company under applicable securities law definitions.
  • Signed by CEO: The report was signed by Steven L. Hoerter, President and Chief Executive Officer, as Principal Executive Officer.

MBX 4291 Phase 1 Cohort Progress and Q2 Financial Disclosure

According to the filing, MBX Biosciences, Inc. (Nasdaq Global Select Market: MBX) is a Delaware-incorporated bioscience company focused on endocrine and metabolic disorders, with its principal executive offices located in Carmel, Indiana. The company furnished its second-quarter 2026 financial results via a press release attached as Exhibit 99.1, though the filing itself does not detail specific financial figures within the body of the report.

On the clinical side, the filing disclosed that the company's MBX 4291 program is advancing through a Phase 1 trial. The first cohort of Part C, the 12-week multiple ascending dose portion of the trial, is enrolling adult participants with obesity defined as a body mass index of 30 or greater. The titration regimen being evaluated consists of 30 mg administered once weekly for four weeks, followed by 120 mg once monthly, and then 180 mg once monthly, according to the filing. The company stated it remains on track to report data from this cohort in the fourth quarter of 2026.

The filing noted that statements regarding the timing of data from the MBX 4291 trial are forward-looking in nature and are subject to risks including those related to clinical development activities, regulatory approvals, dependence on third parties, and the company's financial condition and need for additional funding. The company characterized these forward-looking statements as based on management's current expectations and subject to risks described in prior regulatory filings, including its Annual Report on Form 10-K for the year ended December 31, 2025.

What Was Disclosed

MBX Biosciences filed a Current Report disclosing Q2 2026 financial results, a clinical progress update for MBX 4291 Phase 1 Part C, and an updated corporate presentation, all dated August 6, 2026, and signed by President and CEO Steven L. Hoerter.